Related references
Note: Only part of the references are listed.Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines
Ahmet Altun et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
A cohort study of digoxin exposure and mortality in men with prostate cancer
Evelyn M. Flahavan et al.
BJU INTERNATIONAL (2014)
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis
Ewa Pomianowska et al.
BMC CANCER (2014)
Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial
Akira Mitsuhashi et al.
CANCER (2014)
Early repositioning through compound set enrichment analysis: a knowledge- recycling strategy
Gergely Temesi et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Metformin is associated with improved survival in endometrial cancer
Emily M. Ko et al.
GYNECOLOGIC ONCOLOGY (2014)
Genomics-Enabled Drug Repositioning and Repurposing Insights From an IOM Roundtable Activity
Aidan Power et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Rational drug repositioning by medical genetics (vol 31, pg 1080, 2013)
Zhong-Yi Wang et al.
NATURE BIOTECHNOLOGY (2014)
How Thalidomide Works Against Cancer
A. Keith Stewart
SCIENCE (2014)
Fertility Preservation via Photodynamic Therapy in Young Patients With Early-Stage Uterine Endometrial Cancer A Long-term Follow-up Study
Min Chul Choi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis
Ioannis D. Gallos et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2012)
Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review
Camille C. Gunderson et al.
GYNECOLOGIC ONCOLOGY (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Hiroshi Noto et al.
PLOS ONE (2012)
Identification of Molecular Mechanism for Actions of Existing Medicines and Its Application for Drug Development
Tohru Mizushima
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2012)
Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians
Hiroshi Noto et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Prospective evaluation of insulin resistance among endometrial cancer patients
Jennifer K. Burzawa et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2011)
Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
L. Minig et al.
ANNALS OF ONCOLOGY (2011)
SIGNIFICANTLY INCREASED RISK OF CANCER IN PATIENTS WITH DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Hiroshi Noto et al.
ENDOCRINE PRACTICE (2011)
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
James H. Kim et al.
TOXICOLOGICAL SCIENCES (2011)
A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer
Robert Mutter et al.
CLINICAL CANCER RESEARCH (2009)
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals
Jessica L. Long et al.
AIDS (2008)
Mortality and morbidity of HIV infected patients receiving HAART: A cohort study
George Panos et al.
CURRENT HIV RESEARCH (2008)
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Dipak Panigrahy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines
Elizabeth E. Girroir et al.
TOXICOLOGY (2008)
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers
Bing Xin et al.
CANCER (2007)
Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis
Ambra Pozzi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-δ signaling in epithelial ovarian cancer
Takiko Daikoku et al.
CANCER RESEARCH (2007)
Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer
Yoshihito Yokoyama et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers
Bing Xin et al.
PATHOLOGY & ONCOLOGY RESEARCH (2007)
Cellular and molecular consequences of peroxisome proliferator-activated receptor-γ activation in ovarian cancer cells
Sara Vignati et al.
NEOPLASIA (2006)
1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways
Ping Lei et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The role of thalidomide in multiple myeloma
Chris Schwab et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Peroxisome-proliferator-activated receptor ot agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1
R Grau et al.
BIOCHEMICAL JOURNAL (2006)
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir
MZ Dewan et al.
BLOOD (2006)
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis
MD Castellone et al.
SCIENCE (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Cancer risk in the swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy
GM Clifford et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
CJ Nicol et al.
CARCINOGENESIS (2004)
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E-2, a survival factor for tumor and associated vasculature
TW Davis et al.
CANCER RESEARCH (2004)
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study
JT Thigpen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review
PT Ramirez et al.
GYNECOLOGIC ONCOLOGY (2004)
AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): A model of the interplay of the immune system, virus, and cancer. On the offensive - The Trojan horse is being destroyed - Part A: Kaposi's sarcoma
TW Cheung
CANCER INVESTIGATION (2004)
Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer
WH Gotlieb et al.
OBSTETRICS AND GYNECOLOGY (2003)
被撤回的出版物: Regulation of cyclooxgenase-2 mRNA stability by taxanes - Evidence for involvement of p38, MAPKAPK-2, and HuR (Retracted article. See vol. 295, pg. 293, 2020)
K Subbaramaiah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells
R Salcedo et al.
BLOOD (2003)
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor
FG Buchanan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
COX-2 inhibitors as radio sensitizing agents for cancer therapy
TW Davis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
G Ferrandina et al.
ANNALS OF ONCOLOGY (2002)
PPAR and immune system - what do we know?
X Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer - Evidence for involvement of AP-1 and PEA3
K Subbaramaiah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cyclooxygenase-2 expression during carcinogenesis in the human stomach
BP van Rees et al.
JOURNAL OF PATHOLOGY (2002)
Prostaglandin E-2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy
R Pai et al.
NATURE MEDICINE (2002)
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice
M Sonoshita et al.
NATURE MEDICINE (2001)
Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome
T Kaku et al.
CANCER LETTERS (2001)
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy
DK Gaffney et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion
HS Ryu et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
